BMS Acquisition Announcement
Celgene is now part of Bristol-Myers Squibb creating a leading biopharma company positioned to help address the needs of patients with serious diseases.
From February 1, 2020, all new funding applications must be submitted through the Bristol-Myers Squibb Corporate Grants and Giving website. For Independent Medical Education (IME) and Scientific Advancement Grant (SAG) requests such as fellowships, investigator awards and closed/invite-only scientifically-based meetings, please refer to the Corporate Giving FAQ link below for more information.
To submit an application for an independent medical education (IME) grant, please visit: https://www.bms.com/about-us/responsibility/IME.html
To submit an application for a Scientific Advancement Grant (SAG), please visit: https://bms.com/about-us/responsibility/corporate-giving.html
Please refer to the following for more information:
If you have already submitted an application through Celgene systems and have not received a decision, please do not submit a duplicate application. Bristol-Myers Squibb will review all pending applications, and will get back to you as soon as possible with a decision.
Many thanks for your continued patience during this transition period.
Otezla Divestiture Announcement
As a result of the acquisition of Celgene by Bristol-Myers Squibb, and the divestiture of Otezla® to Amgen, funding requests related to Otezla® (dermatology, rheumatology and Behcet’s Disease) are no longer being accepted on Celgene’s funding portal.
As of Thursday, November 21, 2019, Amgen will accept related funding requests as follows:
BMS Integration Information
How will the Celgene funding process including IME change, and what is the timing of the changes?
Until further notice, there will not be any changes to Celgene’s funding process, and funding requests may continue to be submitted via the current Celgene process.
During this transition period, BMS and Celgene will jointly review requests as a team to avoid duplication of funding.
If my organization has received funding from both Celgene and BMS in the past, should I continue to submit requests to both organizations?
You may submit funding requests to Celgene or BMS, but only one request per activity will be accepted. Do not submit a request for the same activity to both Celgene and BMS. During this transition period, we will jointly review requests as a team to avoid duplication of funding.
What happens if I have current requests pending with both Celgene and BMS?
At this time, no further action is required on your part. During the transition period, both the Celgene and BMS Corporate Giving teams will jointly review requests to avoid potential duplication of funding.
How will the review timelines for Corporate Giving requests including IME be impacted during the transition period?
Until further notice, funding requests submitted to Celgene will continue to follow the current process. During the transition period, there may be delays in processing your request. We thank you in advance for your patience.
Will the review criteria change?
No. Funding requests submitted to Celgene will be reviewed under the same criteria until further notice and the transition is complete.
Will there be changes in the types/scope of requests supported?
Through the transition period, there will not be any changes to the types or scope of requests supported by the Celgene funding process. During the first quarter of 2020, Celgene and BMS plan to unify funding processes. Updates will be provided accordingly.
Will the therapeutic areas of interest for Celgene funding support change?
No, Celgene will continue to support requests in the current therapeutic areas of interest that are posted on our website . During the first quarter of 2020, Celgene and BMS plan to unify funding processes. Updates will be provided accordingly.
Who do I contact if I have questions about the transition process?
Independent Medical Education (IME) or Scientific Advancement Grants (SAG):
–For General questions and Status of a specific request, please email: email@example.com
–For Technical support, please email:
Donations, Sponsorships, Exhibits, or Corporate Memberships:
—For General questions or Status of specific request, please email: firstname.lastname@example.org
–For Technical support, please access Celgene’s funding page: https://www.celgene.com/responsibility/funding/.
From the ‘Types of Support’ section, select the appropriate funding type. Click on “Click Here if Applying,” then click “Continue.” Click “Need Support” (at bottom of page), then click “Still have a question” (at bottom of page), complete ‘Support Request’ form and click “Submit.”
Independent Medical Education (IME) Specific Transition FAQs
How will RFEs or RFPs (Request for Education/Request for Proposals) be reviewed in the interim period?
Celgene may post RFPs aligned to key areas of interest and where applicable may review grant applications in response to these RFPs. Review criteria will remain the same until a unified process between Celgene and BMS is established.
Can I still submit a funding request related to Otezla?
As of October 30th, 2019, no funding requests related to Otezla® (dermatology, rheumatology and Behcet’s Disease) are being accepted. Check back on this site periodically for instructions on how to submit future requests to Amgen.
Celgene will consider funding educational grants for independently developed educational activities for U.S. Healthcare Professionals (HCPs) and researchers in response to unsolicited requests from appropriate external organizations.
Eligible grant requesting organizations include hospitals (academic and community), professional/medical associations and societies, patient advocacy organizations and medical education companies. Independent Medical Education programs may be accredited/certified (e.g., eligible for continuing education credit by the applicable state professional licensing board or specialty board) or non-accredited and may also include Quality Improvement Education (QIE) programs where activities are independently developed and deployed within health systems to address quality measures or indicators aligned to Celgene therapeutic areas (TA) of interest.
Educational Grants are awarded in support of high quality, independent medical educational programs and materials which demonstrate the potential to improve patient care and health outcomes.
Each educational grant awarded must adhere to and be compliant with:
- FDA Final Guidance on Industry-Supported Scientific and Educational Activities
- Office of Inspector General (OIG) Guidelines
- Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support
- Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals
- American Medical Association (AMA) Ethical Guidelines for Gifts to Physicians from Industry
- Other relevant guidelines and regulations
For information on grant support for programs targeting non-U.S. healthcare professionals, please contact the appropriate global office via: https://stgcelg1.com/global-office-network/